Funding for this research was provided by:
KWF Kankerbestrijding (KUN2015-7626)
Radboud Institute for Health Sciences (n/a)
Received: 8 January 2020
Accepted: 12 March 2020
First Online: 24 March 2020
Ethics approval and consent to participate
: Ethics approval was acquired from the regional ethics committee CMO Arnhem-Nijmegen (2015-1773) in NL, London Central NHS Research Ethics Committee (16/LO/0925) in UK, and the Regional Ethical Review Board at the Karolinska Institutet Stockholm (2017/375-31/2) in SE. Written (NL, UK) or verbal (SE) informed consent was obtained from all participants prior to the start of the FGDs. Verbal consent was obtained in Sweden, since this is the standard practice which was approved by the abovementioned ethics committee.
: Not applicable.
: The authors declare that they have no competing interests.